# PTX3-targeted Antifungal Prophylaxis

> **NCT03828773** · NA · RECRUITING · sponsor: **Bochud Pierre-Yves** · enrollment: 410 (estimated)

## Conditions studied

- Candidiasis
- Fungal Infection
- Acute Myeloid Leukemia
- Genetic Predisposition
- Aspergillosis

## Interventions

- **DRUG:** Posaconazole
- **DRUG:** Fluconazole

## Key facts

- **NCT ID:** NCT03828773
- **Lead sponsor:** Bochud Pierre-Yves
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-02-11
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828773, "PTX3-targeted Antifungal Prophylaxis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03828773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*